700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Pancreatic cancer is an aggressive and devastating cancer that continues to have high 5-year mortality rates despiteadvancements in the field. Surgery remains the only curative treatment; however, most patients present with late stagedisease deemed unresectable. By refining the resection guidelines to include a borderline resectable group, as well asadvancements in neoadjuvant chemotherapy and radiation that improve resectability, we may improve upon outcomes forpatients with more invasive disease. Here we summarize and discuss findings presented at the 2014 ASCO GastrointestinalCancers Symposium (Abstracts #283, #302, #309, #274, #275, #327) that relate neoadjuvant therapeutic strategies andborderline resectable cancers.